Curanex Pharmaceuticals Common Stock
CURX | NASDAQ
$5.20
+$0.04 (+0.78%)
Nov 2, 2026, 10:35 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 69.34K | 69.34K | 34.29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -69.34K | -69.34K | -34.29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -10.55M | -7.28M | -4.24M | -1.29M | -435.77K | -422.31K | -365.06K | -239.14K | -137.07K | -92.87K | -12.67K |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -10.47M | -7.24M | -4.23M | -1.29M | -435.03K | -418.89K | -361.51K | -237.01K | -137.07K | -92.87K | -12.67K |
Net Income | -10.47M | -7.24M | -4.23M | -1.29M | -435.03K | -418.89K | -361.51K | -237.01K | -137.07K | -92.87K | -12.67K |
Selling & General & Admin | 2.68M | 2.01M | 1.22M | 532.88K | 361.1K | 347.64K | 290.39K | 239.14K | 137.07K | 92.87K | 12.67K |
Research & Development | 7.83M | 5.24M | 2.98M | 677.47K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -35.04K | -35.04K | n/a | 74.68K | 74.68K | 74.68K | 74.68K | n/a | n/a | n/a | n/a |
Operating Expenses | 10.48M | 7.22M | 4.2M | 1.29M | 435.77K | 422.31K | 365.06K | 239.14K | 137.07K | 92.87K | 12.67K |
Interest Expense | 4.09K | 7.18K | 8.54K | 8.54K | 4.45K | 1.36K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.55M | 7.28M | 4.24M | 1.29M | 435.77K | 422.31K | 365.06K | 239.14K | 137.07K | 92.87K | 12.67K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.42M | 1.42M | 1.42M | 1.42M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
Shares Outstanding (Diluted) | 1.42M | 1.42M | 1.42M | 1.42M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
EPS (Basic) | -7.38 | -5.10 | -2.98 | -0.91 | -0.31 | -0.30 | -0.26 | -0.17 | -0.10 | -0.07 | -0.01 |
EPS (Diluted) | -7.38 | -5.10 | -2.98 | -0.91 | -0.31 | -0.30 | -0.26 | -0.17 | -0.10 | -0.07 | -0.01 |
EBITDA | -10.43M | -7.18M | -4.16M | -1.16M | -329.8K | -331.78K | -290.39K | -239.14K | -137.07K | -92.87K | -12.67K |
EBIT | -10.52M | -7.28M | -4.24M | -1.21M | -359.47K | -346.41K | -290.39K | -239.14K | -137.07K | -92.87K | -12.67K |
Depreciation & Amortization | 84.77K | 99.8K | 79.4K | 45.1K | 29.66K | 14.63K | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove CURX